Many countries have already realized the value of the biotech industry and are now aggressively trying to attract foreign companies in this space. But South Korea needs to up the pace to improve regulations and the innovation environment to become a more attractive market, executives at AstraZeneca say.
Innovation Rewards, Regulatory Ecosystem Key To Korea Competitiveness - AZ Execs
Can Build On Clinical Trials Success
AstraZeneca execs talk about the challenges South Korea faces in becoming a more attractive market for investment by global pharma firms and its significance as a site for clinical trials.
More from South Korea
• By
South Korea's LigaChem is kickstarting a growth and globalization drive through a potential future acquisition of UK ADC player IKSUDA.
• By
A new report from a domestic institute on South Korea’s biopharma M&A trends shows a pickup in activity, but that this remains relatively weak and small-scale. It calls for broader domestic government support to build expertise, drive innovation and globalization.
• By
Cross-Asian initiative has already brought several South Korean gene and cell therapy startups and Japanese VCs closer, with further hopes for product development and launches in Japan, regulatory harmonization and gliobalization.
• By
The latest activity in the South Korean biotech sector includes IPOs by Orum and Dongkook Life, as well as progress with ADCs at multiple firms.
More from Business
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.